Literature DB >> 26419955

Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC).

Farr Niere1, Sanjeev Namjoshi2, Ehwang Song3, Geoffrey A Dilly4, Grant Schoenhard5, Boris V Zemelman4, Yehia Mechref3, Kimberly F Raab-Graham6.   

Abstract

Many biological processes involve the mechanistic/mammalian target of rapamycin complex 1 (mTORC1). Thus, the challenge of deciphering mTORC1-mediated functions during normal and pathological states in the central nervous system is challenging. Because mTORC1 is at the core of translation, we have investigated mTORC1 function in global and regional protein expression. Activation of mTORC1 has been generally regarded to promote translation. Few but recent works have shown that suppression of mTORC1 can also promote local protein synthesis. Moreover, excessive mTORC1 activation during diseased states represses basal and activity-induced protein synthesis. To determine the role of mTORC1 activation in protein expression, we have used an unbiased, large-scale proteomic approach. We provide evidence that a brief repression of mTORC1 activity in vivo by rapamycin has little effect globally, yet leads to a significant remodeling of synaptic proteins, in particular those proteins that reside in the postsynaptic density. We have also found that curtailing the activity of mTORC1 bidirectionally alters the expression of proteins associated with epilepsy, Alzheimer's disease, and autism spectrum disorder-neurological disorders that exhibit elevated mTORC1 activity. Through a protein-protein interaction network analysis, we have identified common proteins shared among these mTORC1-related diseases. One such protein is Parkinson protein 7, which has been implicated in Parkinson's disease, yet not associated with epilepsy, Alzheimers disease, or autism spectrum disorder. To verify our finding, we provide evidence that the protein expression of Parkinson protein 7, including new protein synthesis, is sensitive to mTORC1 inhibition. Using a mouse model of tuberous sclerosis complex, a disease that displays both epilepsy and autism spectrum disorder phenotypes and has overactive mTORC1 signaling, we show that Parkinson protein 7 protein is elevated in the dendrites and colocalizes with the postsynaptic marker postsynaptic density-95. Our work offers a comprehensive view of mTORC1 and its role in regulating regional protein expression in normal and diseased states.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26419955      PMCID: PMC4739665          DOI: 10.1074/mcp.M115.055079

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  92 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

Review 2.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

3.  mTOR Strikes Again: mTORC1 Activation Causes Epilepsy Independent of Overt Pathological Changes.

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2014-01       Impact factor: 7.500

4.  Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain.

Authors:  Xu Li; Irina Alafuzoff; Hilkka Soininen; Bengt Winblad; Jin-Jing Pei
Journal:  FEBS J       Date:  2005-08       Impact factor: 5.542

5.  Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation.

Authors:  I J Weiler; S A Irwin; A Y Klintsova; C M Spencer; A D Brazelton; K Miyashiro; T A Comery; B Patel; J Eberwine; W T Greenough
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

6.  Enrichment map: a network-based method for gene-set enrichment visualization and interpretation.

Authors:  Daniele Merico; Ruth Isserlin; Oliver Stueker; Andrew Emili; Gary D Bader
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 7.  Dendritic ion channelopathy in acquired epilepsy.

Authors:  Nicholas P Poolos; Daniel Johnston
Journal:  Epilepsia       Date:  2012-12       Impact factor: 5.864

Review 8.  mTOR complexes in neurodevelopmental and neuropsychiatric disorders.

Authors:  Mauro Costa-Mattioli; Lisa M Monteggia
Journal:  Nat Neurosci       Date:  2013-10-28       Impact factor: 24.884

9.  Western blots versus selected reaction monitoring assays: time to turn the tables?

Authors:  Ruedi Aebersold; Alma L Burlingame; Ralph A Bradshaw
Journal:  Mol Cell Proteomics       Date:  2013-06-10       Impact factor: 5.911

10.  SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs).

Authors:  Dan E Arking; Daniel B Campbell; Heather C Mefford; Eric M Morrow; Lauren A Weiss; Brett S Abrahams; Idan Menashe; Tim Wadkins; Sharmila Banerjee-Basu; Alan Packer
Journal:  Mol Autism       Date:  2013-10-03       Impact factor: 7.509

View more
  13 in total

1.  Neuroproteomics: How Many Angels can be Identified in an Extract from the Head of a Pin?

Authors:  Jeffery L Twiss; Mike Fainzilber
Journal:  Mol Cell Proteomics       Date:  2016-01-04       Impact factor: 5.911

Review 2.  mTOR referees memory and disease through mRNA repression and competition.

Authors:  Kimberly F Raab-Graham; Farr Niere
Journal:  FEBS Lett       Date:  2017-05-27       Impact factor: 4.124

3.  Ubiquitin C-terminal hydrolase L1 (UCH-L1) loss causes neurodegeneration by altering protein turnover in the first postnatal weeks.

Authors:  Anna T Reinicke; Karoline Laban; Marlies Sachs; Vanessa Kraus; Michael Walden; Markus Damme; Wiebke Sachs; Julia Reichelt; Michaela Schweizer; Philipp Christoph Janiesch; Kent E Duncan; Paul Saftig; Markus M Rinschen; Fabio Morellini; Catherine Meyer-Schwesinger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-28       Impact factor: 11.205

Review 4.  Protein Translation and Psychiatric Disorders.

Authors:  Sophie Laguesse; Dorit Ron
Journal:  Neuroscientist       Date:  2019-07-04       Impact factor: 7.519

5.  Chronic Intermittent Ethanol Exposure Selectively Increases Synaptic Excitability in the Ventral Domain of the Rat Hippocampus.

Authors:  Sarah E Ewin; James W Morgan; Farr Niere; Nate P McMullen; Samuel H Barth; Antoine G Almonte; Kimberly F Raab-Graham; Jeffrey L Weiner
Journal:  Neuroscience       Date:  2018-11-24       Impact factor: 3.590

6.  Chronic Social Isolation Stress during Peri-Adolescence Alters Presynaptic Dopamine Terminal Dynamics via Augmentation in Accumbal Dopamine Availability.

Authors:  Anushree N Karkhanis; Amy C Leach; Jordan T Yorgason; Ayse Uneri; Samuel Barth; Farr Niere; Nancy J Alexander; Jeffrey L Weiner; Brian A McCool; Kimberly F Raab-Graham; Mark J Ferris; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2018-10-16       Impact factor: 4.418

Review 7.  Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression.

Authors:  Kimberly F Raab-Graham; Emily R Workman; Sanjeev Namjoshi; Farr Niere
Journal:  Brain Res       Date:  2016-04-26       Impact factor: 3.252

8.  mTORC1 Is a Local, Postsynaptic Voltage Sensor Regulated by Positive and Negative Feedback Pathways.

Authors:  Farr Niere; Kimberly F Raab-Graham
Journal:  Front Cell Neurosci       Date:  2017-05-30       Impact factor: 5.505

Review 9.  Screening the Molecular Framework Underlying Local Dendritic mRNA Translation.

Authors:  Sanjeev V Namjoshi; Kimberly F Raab-Graham
Journal:  Front Mol Neurosci       Date:  2017-02-24       Impact factor: 5.639

10.  mTORC1 controls long-term memory retrieval.

Authors:  Magdalena Pereyra; Cynthia Katche; Ana Belén de Landeta; Jorge H Medina
Journal:  Sci Rep       Date:  2018-06-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.